Cours suspendu

Autres langues Repare Therapeutics Inc.

Actions

RPTX

US7602731025

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 27/01/2026			Varia. 5j.	Varia. 1 janv.
2,650 ^USD	+0,76%		-.--%	+1,92%

03/02	Pyxis Oncology, Inc. annonce des changements à la direction générale, effectifs au 3 février 2026	CI
28/01	Xenotherapeutics Inc finalise l'acquisition de Repare Therapeutics Inc. (NasdaqGS:RPTX) auprès de BVF Partners L.P., Blue Owl Healthcare Opportunities, OrbiMed Advisors LLC et d'autres	CI

Autres langues

03/02	Pyxis Oncology, Inc. Announces Chief Executive Officer Changes, Effective February 3, 2026
28/01	Repare Therapeutics Inc.(NasdaqGS:RPTX) dropped from NASDAQ Composite Index
28/01	Xenotherapeutics Inc completed the acquisition of Repare Therapeutics Inc. from BVF Partners L.P., Blue Owl Healthcare Opportunities, OrbiMed Advisors LLC, and others.
16/01	Repare Shareholders Approve Acquisition by XenoTherapeutics, Inc.
24/12	Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment; Repare Shares Rise
24/12	Repare Therapeutics Shares Rise on $30 Million Asset Deal With Gilead
24/12	Gilead Sciences to Acquire Repare Therapeutics' Investigational Cancer Treatment
24/12	Repare Therapeutics Announces Acquisition Of Pol? ATPase Inhibitor, RP-3467, By Gilead Sciences For Up To $30 Million In Total Consideration
24/12	Repare Therapeutics Announces Acquisition of Polθ ATPase Inhibitor, RP-3467, by Gilead Sciences for Up To $30 Million in Total Consideration
19/12	Repare Therapeutics Inc. Announces Resignation Ofmichael Zinda as Chief Scientific Officer, Effective December 31, 2025
20/11	Repare signs support agreements with key shareholders for Xenotherapeutics deal
20/11	Repare Therapeutics Enters into Support and Voting Agreements with Significant Shareholders for Proposed Transaction with XenoTherapeutics, Inc.
14/11	Repare Therapeutics Agrees to Be Acquired by XenoTherapeutics; Shares Halted
14/11	Repare Therapeutics Enters into Definitive Agreement to be Acquired by XenoTherapeutics, Inc.
14/11	Repare Therapeutics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025
14/11	Xenotherapeutics Inc signed a definitive arrangement agreement to acquire Repare Therapeutics Inc. for $78.7 million.
13/10/25	Repare Therapeutics to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
13/10/25	Repare Therapeutics Inc to Present Initial Data from Phase 1 LIONS Clinical Trial at 37th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
22/09/25	Repare Therapeutics Inc.(NasdaqGS:RPTX) dropped from S&P Global BMI Index
08/08/25	Repare Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025
08/08/25	Repare Therapeutics Q2 net loss narrows to $16.7 mln
08/08/25	Repare Therapeutics Provides Business Update and Reports Second Quarter 2025 Financial Results
15/07/25	Repare Signs Licensing Deal With Debiopharm for Lunresertib
15/07/25	Repare Therapeutics Inc. Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib
15/07/25	Repare Therapeutics enters exclusive worldwide licensing agreement with Debiopharm for Lunresertib